MedTrace Logo

A Study to Evaluate the Safety and Tolerability of RO7296682 in Participants With Advanced Solid Tumors

NCT04158583 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2024-03-04

Study results available
· View outcomes & findings →

Summary

This study was planned to evaluate the safety and tolerability of RO7296682 in participants with advanced solid tumors.

Conditions

Interventions

DRUG

RO7296682

RO7296682 will be administered by the schedules specified in the respective arms.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-09
Primary Completion
2022-07-21
Completion
2022-07-21
FDA Drug
Yes

Countries

  • Australia
  • Belgium
  • Canada
  • Denmark
  • Spain

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04158583 on ClinicalTrials.gov